Have you attempted diet and exercise programs
For cardiovascular benefits, the timeline extends further
All samples were assayed in duplicate
Thats a conversation to be had, and I really want listeners to hear that clearly
Key questions remain around access, long-term use, and how healthcare can manage these costs while delivering downstream value
6 Since then, states have altered their positions on covering anti-obesity GLP-1 therapies: Four have withdrawn coverage entirely (California, New Hampshire, Pennsylvania, and South Carolina), three have added coverage (Missouri, Tennessee, and Utah), and at least two states (Michigan and Virginia) have enacted more narrow utilization criteria, limiting future use to those with morbid obesity